eFFECTOR Therapeutics Inc (STU:LWK)
€ 9.25 0 (0%) Market Cap: 29.23 Mil Enterprise Value: 31.69 Mil PE Ratio: 0 PB Ratio: 0.23 GF Score: 21/100

eFFECTOR Therapeutics Inc Update on Expanded Development of Zotatifin - Corporate Call Transcript

Jun 05, 2022 / 11:00PM GMT
Operator

Ladies and gentlemen, please remain on your lines. The eFFECTOR Therapeutics Zotatifin Program Update and Expansion Plans conference call will begin momentarily. Once again, please remain on your lines, your conference call will begin momentarily. Thank you.

Ladies and gentlemen, thank you for standing by and welcome to eFFECTOR Therapeutics Zotatifin Program Update and Expansion Plans conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. (Operator Instructions).

It is now my pleasure to introduce Chief Financial Officer Michael Byrnes.

Michael Byrnes
eFFECTOR Therapeutics - CFO

Thank you. Good evening and thank you for joining us today to review eFFECTOR's zotatifin program update and expansion plans. Before we start, we encourage you to view the slides for this webcast as well as the press release issued earlier today. Both of which are accessible on our Web site in the Investors section.

As shown on Slide 1, during today's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot